Just a moment, the page is loading...

GSK-49653/140




A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Effects of Rosiglitazone on Post Prandial Glycaemia in Type 2 Diabetic Patients.
rosiglitazone
49653/140
Diabetes Mellitus, Type 2
Phase 3
An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.
February 2015